Biomarkers for oralization during long-term proton pump inhibitor therapy predict survival in cirrhosis
Abstract Proton pump inhibitors (PPI) are an invaluable therapy option for acid related diseases; however, PPI therapy is also linked to a series of side effects in cirrhosis, such as microbiome alterations, spontaneous bacterial peritonitis and hepatic encephalopathy. Decision tools to balance bene...
Main Authors: | , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Publishing Group
2019-08-01
|
Series: | Scientific Reports |
Online Access: | https://doi.org/10.1038/s41598-019-48352-5 |